By Jamie L. Pearson, New Holland Group and Cliff Giesenow, CanX Consulting

Every emerging cannabis market has a story arc. Thailand was a thriller, with fast pivots, political cliffhangers, and regulatory reversals every eighteen months. Germany was a procedural drama, methodical, compliance-heavy, deeply unsexy, until suddenly it wasn’t. South Africa? South Africa is a Western. Big sky, wide open territory, hundreds of years of history with Cannabis (think Durban Poison), and a cast of characters who showed up before the rules were written for a green gold rush that everyone can see coming, but nobody has fully mapped. Welcome to CannaLand.

The country has an estimated 2,000+ consumption clubs and dispensaries operating across its suburbs, modelled loosely on the Spanish private-use club framework, since Cannabis was decriminalized in 2018, for ‘private’ use and cultivation. Products range from precision pharmaceutical flower to 500mg+ infused beverages. Pre-rolls are the fastest-growing format. Edibles are strong. Packaging rules are nonexistent since there is no regulation yet for commerce. And law enforcement is largely absent from the space, so it is very much the Canna Wild West. The Department of Trade and Industry, now a primary driver of cannabis and hemp policy alongside SAHPRA (the health regulator) and DALRRD (the agri department), tacitly supports the direction of travel. None of this is officially ratified. All of it is very much real.

South Africa is gearing up to be a cultivation and production powerhouse because it also happens to be one of the best places on earth to grow cannabis. The ‘Emerald Triangle of Africa’ has vast tracks of land at high altitude with intense UV exposure, pristine unfarmed soil in many regions, low labor costs, high competency levels, and decades of native cultivation experience, not to mention its very own landrace strains. Some licensed facilities are now producing clean-COA, full-spectrum flower, in living soil, and sun grown, at price points that undercut European indoor operators significantly. South Africa is also a PIC/S member country, which means finished, patient-ready, packed pharma products produced there carry the regulatory credibility needed for the most demanding import markets.

A broad National Cannabis Master Plan has been under development for several years. When fully implemented, it has the potential to create one of the most progressive cannabis regulatory frameworks globally: integrating cannabis and hemp across industrial, medical, and commercial applications in a single coherent structure. That moment hasn’t arrived yet. But the groundwork is visible.

If you’re coming to the International Cannabis Business Conference and trying to get your bearings before you walk into a meeting, here’s your cheat sheet, framed the only way that makes a crowded cast of characters actually stick.

CATEGORY I: THE EXPORT LEADERS

SafriCanna: The Lion King
GACP + EU-GMP certified | largest medicinal cannabis producer in Africa | Johannesburg

This is the origin story. The rightful heir to the throne built from the ground up with the full understanding that what they were constructing had to be worthy of a kingdom. SafriCanna earned its GACP cultivation license early on in 2020, followed by EU-GMP approval and CUMCS certification in 2021, and has since positioned itself as the largest medicinal cannabis producer on the African continent. Like Simba returning to Pride Rock, SafriCanna didn’t rush the moment. They built the compliance infrastructure, assembled a pharmaceutical-grade team, and arrived at the export conversation fully credentialed. In a market where operators constantly oversell their readiness, SafriCanna is the one that did the work before making the announcement. If you’re looking for the operator who set the standard for what South African cannabis should look like on a European pharmacy shelf, the circle of life starts here.

MedCan: Apollo 13
One of the first SA companies to export high-THC flower commercially | first to land product in the UK | indoor GMP, Johannesburg

“Houston, we have a problem”, except they solved it. MedCan is the first South African company to export high-THC cannabis flower commercially to the United Kingdom. That sounds straightforward until you understand what it took: years of navigating SAHPRA licensing, building a fully indoor GMP-certified facility in a former beer warehouse in Johannesburg, and threading the needle of UK import compliance at a moment when almost no one had done it from this continent before. Apollo 13 didn’t land on the moon, but its engineers solved problems in real time under real pressure and brought something home that wasn’t supposed to make it. That’s MedCan. The UK export wasn’t a press release moment. It was five years of engineering.

Felbridge Medical (Limberlost): First Man
First commercial export of dry cannabis flower from SA to Europe (320kg to Switzerland, 2021) | 14,000m² Stellenbosch greenhouse | genetics distributor across Africa

Before anyone else had done it commercially, the Zetler family did. Four generations of Stellenbosch farming, strawberries and hydroponic peppers first, then in 2019 a pivot into a 14,000-square-metre licensed cannabis facility. In June 2021, Felbridge completed South Africa’s first commercial export of dry cannabis flower, shipping 320kg to Switzerland under a multi-year offtake agreement. First Man isn’t the most glamorous Neil Armstrong story; it’s the quiet one about what it costs to get there first. Felbridge is that film. They’re also the licensed African distributor for Swiss genetics house Puregene and co-operate with Perfect Plants (Netherlands) to supply tissue culture, seeds, and clones to licensed producers across the continent. Julian Zetler (CEO) and Leslie Zetler have since moved broader operations under the Limberlost umbrella. If you’re sourcing genetics or looking for an established offtake anchor in the Western Cape, this is the name that was there before the road existed.

Biogenetics Labs: The Terminal
EU-GMP principles | pharmaceutical-grade cultivation | Johannesburg, Gauteng | supply chain built for European regulatory requirements

Viktor Navorski didn’t panic when stranded in the airport; he adapted a routine that sustained him until the exit door opened. Biogenetics Labs is doing the same thing in Johannesburg, quietly building a pharmaceutical-grade supply chain, hand-picked harvests, batch-level documentation, and EU-GMP-aligned quality oversight. This is all in place before the European clinical channels fully open to South African-origin products. Their pitch is reliability over novelty, consistent flower performance, batch-to-batch repeatability, and a distribution story calibrated for pharmacies and clinics rather than for trade show booths. In a market where operators often announce before they’ve built, Biogenetics is a future leader that still needs to prove it can scale. Worth a conversation if you’re a European distributor looking for a second SA source with a clean paper trail. (www.biogenetics.co.za)

Blommed: No Country for Old Men

Anton Chigurh never announced himself. He simply arrived, completed the job, and left a result that was impossible to argue with. Blommed, experienced salad ingredient farmers who moved into Cannabis, quietly executed shipments into Germany in 2025, demonstrating what matters most in this market: regulatory alignment, consistency, and the ability to deliver. No Country for Old Men is not a film about noise; it is a film about the person in the room who knows what they are doing while everyone else is still talking. In a market full of announcements, Blommed represents well-planned execution.

ChroniCo: Groundhog Day

Bill Murray wakes up. Same day. He does it again. And again. And again. The point is not the repetition; it is what the repetition proves. ChroniCo has done what many claim and few deliver: repeat exports across multiple jurisdictions. Not once, not as a headline, but consistently. In a global medical market that values reliability over narrative, repetition is the only credential that matters. Multiple confirmed exports across several countries place ChroniCo in a category most SA operators are still working toward. They have run this day before. They know how it ends.

CATEGORY II: THE INFRASTRUCTURE BUILDERS

ImpiloVest/Afriplex: 2001: A Space Odyssey
First SA cannabis processing license | pharmaceutical-grade API extraction | EU/South America/Far East JVs | R1 billion revenue target

Some films don’t make complete sense until you understand what they were building toward. Afriplex, the first company in South Africa to hold a cannabis processing license, now operating within ImpiloVest alongside Releaf Pharmaceuticals, is the foundational infrastructure layer that the entire South African pharmaceutical cannabis story is built on. Processing is not the glamorous part of this industry. Nobody comes to the International Cannabis Business Conference to talk about extraction yields and API purification protocols. But without processing infrastructure, cultivators have biomass, not product. Afriplex is HAL 9000, the intelligence embedded in the system that makes everything else possible. The monolith that appeared before anyone understood why. In 2026, as South Africa begins to scale its processing ambitions, the company that built the first factory is going to become a great deal more legible to the international operators who are finally ready to take the market seriously.

CiloCybin: Citizen Kane
First GACP + GMP license in SA | JSE-listed | large-scale extraction + GMP manufacturing | primary supply to Australia | EU pathway in progress

Citizen Kane opens with a mystery: Rosebud. It then works backward through the layers of an institution to understand how it was built. CiloCybin holds a unique position as one of the earliest license holders in the country, the only cannabis-focused entity listed on the Johannesburg Stock Exchange, and one of the largest GMP extraction and processing facilities in Africa, capable of processing 250kg of biomass per day, scalable to 1,000kg. Their current supply flows primarily to Australia, but they have eyes on the UK, and their EU pathway is in progress. In a market that is still defining its institutional backbone, CiloCybin represents the bridge between capital markets and industrial-scale cannabis infrastructure. The question the market is now asking about CiloCybin is the same one Kane asked about Rosebud: “How does the full story end?”

Delta Nine Pharma: The Big Short
Post-harvest EU-GMP processing | Cape Winelands | toll manufacturer for SAHPRA-licensed cultivators

The Big Short’s most important insight wasn’t about the banks. It was about the people who understood the plumbing of the system better than anyone else. Delta Nine Pharma is the plumbing play in South Africa’s cannabis value chain. Based in the Cape Winelands, they’re a specialist post-harvest processor, drying, trimming, curing, packaging, and batch traceability, working with SAHPRA-licensed cultivators who don’t have the GMP processing infrastructure in-house. In a market where most cultivators are growing flower they can’t legally finish into export-ready product themselves, Delta Nine is the conversion layer. Small footprint, critical function. If South Africa’s export volume scales the way the trajectory suggests, toll processors like Delta Nine become infrastructure. The smart money already knows this.

GES Labs: Julie & Julia

The whole film takes place in the kitchen, not on the farm. Julie & Julia is not about growing the ingredients; it is about what a skilled hand does with them. GES Labs is emerging as one of the more advanced product development and formulation companies in South Africa, supported by German pharmaceutical partnerships. Their strength is not cultivation. It is what happens after harvest. As global markets shift toward finished, patient-ready products, the formulation and API layer becomes increasingly valuable. Worth tracking closely as the SA export story matures beyond dried flower.

Verve Dynamics/Triton Pharmaceuticals: Inception

You build the first layer. Then you build the layer beneath that. Then you build the layer beneath that. Inception is a film about infrastructure that only reveals its full purpose once you are already inside it. Verve Dynamics and Triton Pharmaceuticals are two companies to watch as the South African market matures into a processing and product-driven ecosystem. Both are focused on cannabis and broader botanical applications, with infrastructure designed to plug into international supply chains. They are not yet headline names, but they are both experienced operators and are delivering a wide variety of finished patient-ready products to some key markets. The deeper you go, the more deliberate the architecture looks.

EcoGreen Analytics: A Few Good Men (And women)

Trusted results underpin the whole medical Cannabis industry, and these guys have positioned themselves as the go-to in SA. The truth? It is all about knowing the truth and handling it, and that is what these guys do as the leading testing laboratory in the region. A powerhouse husband and wife team, with him being the 30-year lab veteran and her the CEO, this duo is helping to shape the industry as one of the only dedicated cannabis, botanical, and psychedelic ISO17025 certified labs in the region.

CATEGORY III: THE GENETICS & CULTIVATION SPECIALISTS

Rascal Medcan: Moneyball
SAHPRA GMP license (2021) | License to Manufacture Medicines (2023) | aeroponic system | tissue culture | Mother Labs genetics | Christiana, North West | 130 employees

Nobody watched Rascal’s first at-bat and said, “that’s the future of cannabis cultivation.” They watched a potato company. Established in 1993 as South Africa’s first private producer of certified disease-free generation-0 Mini tubers, Rascal controls approximately 70% of the South African potato seed market and produces over 7 million Mini tubers annually. When cannabis licensing opened, they relied on their agricultural know-how and played the numbers. Their aeroponic cultivation method, developed over decades for potatoes, transfers directly to cannabis, delivering precision nutrient control, scalable yields, and pathogen-free propagation. They’ve partnered with Mother Labs (Saskatchewan) for premium genetics in the 22–30% THC range. Moneyball wins with data, not scouts. Rascal wins with systems, not stories.

BioCann: Contagion
3,500m² indoor facility | 50,000+ plants/year | GMP + GACP + CUMCS certified | Segra International genetics | exporting to international pharmaceutical companies | Section 21 domestic access

Contagion is a film about systems that contain and channel something powerful before it spreads the wrong way. BioCann is one of the first South African cannabis producers to have met SAHPRA regulations, dating to 2020, and they’ve built methodically since, a 3,500-square-metre indoor facility capable of producing over 50,000 plants per year, certified under GMP, GACP, and CUMCS, with genetics sourced from Segra International, a global leader in cannabis plant genetics. They’re exporting to international pharmaceutical companies and running a Section 21 domestic access program for cancer patients, supplying medical-grade product free of charge to patients who cannot otherwise access it. The operators who build both an export story and a domestic patient story will be the ones who survive the regulatory transition when commercial retail eventually opens. BioCann has built both.

Beyond Buds: Into the Wild
SAHPRA GACP + GMP licensed | Keisie Valley, Western Cape | 80% renewable energy | international pharmaceutical markets

Into the Wild is about someone who deliberately chose the hardest, most beautiful place to do something extraordinary, and built something real in the process. Beyond Buds set up their cultivation facility in the Keisie Valley, surrounded by the Langeberg mountains in the Western Cape, not the most obvious choice for a pharmaceutical-grade cannabis operation, but entirely intentional. Founded in 2020, Beyond Buds powers approximately 80% of its operations through natural energy. Their pitch to international buyers is consistency, purity, and a sustainability narrative that increasingly matters to European clinical procurement teams. A boutique operator with serious credentials and a story that travels well.

ILCO Farming: Perfume: The Story of a Murderer

Grenouille was not interested in the flower itself. He was obsessed with what the flower released. Perfume is a film about the invisible quality that makes one thing extraordinary and another forgettable. ILCO Farming has built its entire identity around that invisible quality, terpene expression at 3 to 4%, strong quality metrics, and a clear focus on premium craft cultivation outcomes. In a market where most operators compete on THC percentages and volume, ILCO leans into biochemical differentiation. That positioning speaks directly to European clinical buyers who are moving beyond basic potency specifications. The nose knows.

BudGrow: High Noon

Will Kane does not make speeches. He straps on his badge, walks into the street at exactly midday, and handles the situation. High Noon is a film about the operator who simply does what they said they would do, when they said they would do it, without requiring an audience. BudGrow is a well-built facility executing consistently. Not the loudest name in the market, but a reliable one that has paid school fees and adapted. In this environment, reliability is the rarest currency. The clock strikes twelve. BudGrow is already there.

CATEGORY IV: THE CROSS-BORDER CAPITAL PLAYS

Instadose Pharma Corp (SA Operations): The Revenant
Canada-based | SA cultivation operations | 2.125-ton shipment to North Macedonia (December 2021), the largest single documented SA export at the time

Like Leonardo DiCaprio crawling through the snow, it wasn’t elegant. But it was real, it was documented, and it proved that the SA-to-international-market supply chain isn’t theoretical. It works. Instadose Pharma, a Canadian company operating cultivation in South Africa, completed a record 2.125-tonne shipment to North Macedonia in December 2021, the largest single documented export from South Africa at the time. They represent the cross-border capital and operational template that international investors looking at South Africa should study, including offshore capital structure, local cultivation execution, and documented export pathway. Worth knowing at the table even if they’re not a pure SA-origin play.

CATEGORY V: THE DOMESTIC MARKET BUILDERS

Cannabis Clinics/Synergy Wellness: Patch Adams
Built off a platform with over 100,000+ patients prescribed globally across 9 countries | telemedicine Section 21 access | largest domestic patient base | most strategically positioned operators for medical cannabis

Patch Adams is not the most technically impressive medical film ever made. But it’s the one about the truly patient-focused doctor. Cannabis Clinics and Synergy Wellness together represent the largest patient-facing operations in South Africa’s regulated cannabis market, telemedicine consultations, Section 21 applications on behalf of patients, and pharmaceutical-grade product delivery to doorsteps. It is worth noting that this compliant medical pathway currently represents less than 10% of total market activity; the rest is happening in the grey and unlicensed channels described below. But as the medical market grows, these platforms will dominate and have built the patient numbers and data. The full legal Commercialization Policy for Cannabis is currently being drafted for public comment before Cabinet approval, with a full Cannabis Bill not expected before Parliament until 2027/28. The operators with the largest existing patient relationship base in the country are extraordinarily well-positioned for a true medical channel to market.

VitaCann Pharm/HempVest Africa: Black Panther
100% Black-owned | Gauteng | seed license, GAP cultivation, CBD extraction | first to produce high-quality CBD flower in SA | dispensary under 22C license | 200–500 employees | Africanna Inc incubator partner

Wakanda didn’t ask for permission to be exceptional. VitaCann Pharma, operating as HempVest Africa, is a 100% Black-owned cannabis company based in Gauteng that was built from the ground up without waiting for the industry’s structural advantages to align in its favor. Partly funded by Africanna, an incubator in the space, HempVest claims to be the first company in South Africa to produce high-quality CBD flower at a commercial scale, and has since expanded to include a seed license, a full-spectrum CBD extraction operation, and a 22C-licensed dispensary subsidiary. With 200–500 employees and government visibility through state assistance, VitaCann is one of the few operators whose domestic and export stories are equally compelling.

SilverLeaf Investments: Facebook
3 investments made at the beginning of a revolution, many lessons learned

Funding a fledgling industry with Venture Capital is all about timing. Too early and you paddle hard to catch the wave, too late and you wish you’d caught it. SilverLeaf Investments was founded in 2021 as an early-stage market entry point for investors looking to capitalize on the green rush and to enable and empower the Cannabis and Hemp industries. Exclusively South Africa focused, and launched around a tax break incentive, the fund has made three investments over the past five years, into a JV cultivation play, into the EcoGreen Analytics testing lab, and into a CBD beverage brand called DOPE drinks that was born in Africa and then skipped the pond over to the exploding hemp derived low dose THC beverage market in the USA. With lessons learnt around the dangers of startups being underfunded, and regulations not quite there yet, being the hokey pokey dance that they often are – one step forward, two steps back, left foot in, right foot out, the fund operators have had to navigate uncertainty, and to paddle hard to stay afloat as the market unfolds and regulations get written.

CannAfrica, Cannamart & The Greenside: Tombstone

Tombstone is set in a town that exists before the law fully arrives. Commerce is already happening. Relationships are already forming. The rules are being written in real time by the people bold enough to show up first. That is South Africa’s retail cannabis market in 2026. Adult use exists. In the grey/black market, and whitish special access/club model market that is South Africa right now. With the estimated 2,000+ dispensaries and consumption clubs scattered across the country, from suburban strip malls to Cape Town’s city bowl, and a booming eCommerce industry, the retail market is already functioning at scale. It has not been formally ratified, but it is very much real and is tacitly supported by the Department of Trade and Industry. CannAfrica (with over 100 stores and franchises) and The Greenside (with 5 innovative Cannaporium wellness stores) are two of the more visible operators demonstrating that this model works at the consumer level. For international brands evaluating South Africa as an entry point into the broader African continent, this is the channel moving fastest. It is also the most useful test-and-learn environment for product formats, dosing, pricing, and consumer behavior before formal regulation arrives. Doc Holliday would approve.

Also in the Room: The Supporting Cast

Every ensemble film has a supporting cast, the characters who don’t anchor a scene, but whose presence tells you something real about the world the story is set in. A few names worth having on your radar, with identifying information available at the time of publication:

Cheeba Academy: empowering, enabling, and uplifting the country and region. These superstar pioneers are accredited by the South African government as a formal training school for the industry. Offering comprehensive cannabis and hemp education, including online or in-person courses on growing, medicine, business, and budtending, gives participants solid credibility and a great start in this fledgling industry. Run by super passionate and competent founders, these guys have educated, promoted, and championed the plant like no other, serving as the strongest advocates for the country and industry. Catch them at expos and with broadcasts and webinars that are super informative, and if you are in SA, pay a visit to their campus and dispensary club.

Rosh Products Manufacturers (Pty) Ltd: a South African manufacturing and distribution company whose cannabis-adjacent role is still developing in public documentation, but which surfaces in industry supplier networks. Worth a direct conversation if you’re exploring local manufacturing partnerships.

Modelpak / TEKGroup: a South African pharmaceutical and industrial packaging group whose infrastructure increasingly serves the cannabis sector. Not an operator, but the kind of supply chain partner whose compliance posture matters to international buyers doing distributor-level due diligence on SA-origin product.

Wellness Choice: associated with Gilbert Richmond, whose network touches the SA cannabis distribution and access space. Relevant if your focus is domestic distribution channel development.

Business Day South Africa: the country’s leading financial newspaper and the publication of record for JSE-listed cannabis company coverage, regulatory announcements, and market data. Required reading if you’re building an SA investment thesis.

A Note on the Outtakes

Perfect Plants: a leading cannabis biogenetics company based in the Netherlands, not South Africa. A relevant genetics supplier for SA operators (Felbridge distributes their genetics under a co-operation agreement), but it belongs in a European market article rather than this one.

Labat Africa: formerly a JSE-listed cannabis holding company, Labat has since exited the cannabis sector and repositioned as a technology-focused holding company, with trading suspended on the JSE. Their cannabis chapter, including CannAfrica, has been recently spun out or sold off. A cautionary tale about the gap between listed-company ambition and operational execution in an early-stage market of uncertainty and slow regulation.

The Credits

South Africa’s cannabis cast is still finding its final form. In film terms, the opening scenes of the first few years are done, now we’re somewhere in the second act, the characters are established, the stakes are clear, and the audience is finally paying attention.

But unlike most second acts, South Africa isn’t waiting for regulation to define the market. The market is already defining itself. The 2% hemp THC threshold that just went into effect means the sequel is already in production. Since 2018, SAHPRA has issued over 100 medical cultivation licenses, 4 manufacturing licenses, and many research permits. DALRRD has issued over 1,400 cumulative hemp permits as of September 2025. And the possibility now exists for South Africa, if it can get it right, to soon have the most progressive Cannabis laws in the world, including finding a way to involve the nearly 1 million subsistence farmers who have been growing this plant there for generations, as a legacy illicit supply to Europe and the UK. The numbers tell the story.

And the geography and history do too. This is not a market to watch from the sidelines. It is a potential global powerhouse down south. It is Africa rising and a market to be in, with the right partners, before the curtain rises on Act Three.

Meet South Africa’s Cast of Characters at the International Cannabis Business Conference in Berlin, April 13-15, 2026.

***

Jamie L. Pearson is the Founder and CEO of New Holland Group, a global advisory firm focused on cross-border expansion strategy. She is an accredited investor, popular speaker, and experienced board member.

Cliff Giesenow is a pioneer in the South African Cannabis industry, with nearly a decade of knowledge, network, and experience in the region. He co-founded the Cannabis Trade Association of Africa and has been a champion for the plant and for his native South Africa’s exploding industry.